-
Alimentary Pharmacology & Therapeutics 1994The clinical efficacy of the proton pump inhibitor pantoprazole has been compared with ranitidine in a number of clinical studies in patients with either duodenal or... (Comparative Study)
Comparative Study Review
The clinical efficacy of the proton pump inhibitor pantoprazole has been compared with ranitidine in a number of clinical studies in patients with either duodenal or gastric ulcer(s) or gastro-oesophageal reflux disease. A pooled analysis of five comparative trials in duodenal ulcer patients showed that healing rates with pantoprazole (40 mg/day) were significantly better than for ranitidine (300 mg/day) at both 2 (P < 0.001) and 4 weeks (P < 0.001). Data from case report forms in one of the studies showed that the improvement in pain relief at 2 weeks was also greater in patients receiving pantoprazole (80%) than in those receiving ranitidine (61%). The healing rates for the treatment of gastric ulcer were significantly higher for pantoprazole than for ranitidine (at 4 and 8 weeks; both P < 0.001), in an analysis of two comparative studies. The pooled pain relief values for pantoprazole and ranitidine did not differ significantly. With gastro-oesophageal reflux disease, the pooled results from two comparative studies showed that pantoprazole (40 mg/day and 80 mg/day) was superior to ranitidine (150 mg twice daily) in healing. In conclusion, pantoprazole, compared to ranitidine, quickens healing and symptom relief in gastroduodenal ulcers, and in reflux oesophagitis it also improves the rate of healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; Duodenal Ulcer; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine; Stomach Ulcer; Sulfoxides
PubMed: 8180294
DOI: 10.1111/j.1365-2036.1994.tb00247.x -
American Journal of Therapeutics Apr 2021
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Granuloma; Humans; Kidney; Nephritis, Interstitial; Pantoprazole
PubMed: 33852474
DOI: 10.1097/MJT.0000000000001368 -
Current Drug Metabolism 2020Cytochrome P450 (CYP450) enzymes play an important role in the metabolism of 70-80% of the currently used medications, including proton pump inhibitors. There are some... (Review)
Review
BACKGROUND
Cytochrome P450 (CYP450) enzymes play an important role in the metabolism of 70-80% of the currently used medications, including proton pump inhibitors. There are some data analyzing the impact of gene polymorphisms of CYP450 enzymes on most widely used PPIs, such as omeprazole, however, the data on pantoprazole are highly lacking.
OBJECTIVE
To summarize the most recent publications and studies on the role of polymorphisms of the genes encoding CYP450 enzyme 2C19 in the metabolism of pantoprazole and pantoprazole based Helicobacter pylori eradication regimens.
METHODS
We performed a non-systematic search of the available literature on the selected topic.
RESULTS AND CONCLUSION
The data on cytochrome P450 gene polymorphisms and their role in pantoprazole metabolism and pantoprazole based Helicobacter pylori eradication remain conflicting. Individual differences in pantoprazole metabolism might be partly related to genetic polymorphisms of CYP450 enzymes. Most of the studies support the observation that cytochrome 2C19 polymorphisms have an impact on the pharmacokinetics of pantoprazole and its therapeutic effects: poor metabolizers of PPIs are more likely to have a better response to pantoprazole therapy and achieve better H. pylori eradication rates compared to rapid metabolizers. The determination of alleles that are associated with decreased (e.g., *2, *3 alleles) or increased (e.g., *17 allele) cytochrome 2C19 enzyme activity might be used as predictive factors for the potential of acid suppression and the success of Helicobacter pylori eradication. Overall, currently available data do not provide robust evidence, therefore, the application of genetic polymorphisms of cytochrome enzymes in clinical practice still cannot be recommended as routine practice for personalized pantoprazole prescription strategies.
Topics: Cytochrome P-450 CYP2C19; Helicobacter Infections; Humans; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors
PubMed: 32407266
DOI: 10.2174/1389200221666200514081442 -
BMJ Supportive & Palliative Care Jul 2022Proton pump inhibitors (PPIs) have become the agents of choice for acid-related diseases. In some clinical situations, PPI therapy by oral or intravenous route may be...
Proton pump inhibitors (PPIs) have become the agents of choice for acid-related diseases. In some clinical situations, PPI therapy by oral or intravenous route may be difficult especially among elderly and patients in palliative care. Off-label PPI subcutaneous injection could be the last alternative to improve patient relief, despite limited published data. We report a case of linitis plastica, peritoneal carcinomatosis and occlusive syndrome who suffered from painful regurgitations which rapidly improved after subcutaneous pantoprazole. No related adverse effects were observed during PPI therapy. Despite some limitations, this report suggests that off-label subcutaneous pantoprazole could be an interesting alternative route when intravenous infusion may be difficult or harmful for elderly and patients in palliative care. Nevertheless, clinical safety and efficiency data on larger populations are needed to validate this use in such population.
Topics: Aged; Humans; Palliative Care; Pantoprazole; Proton Pump Inhibitors
PubMed: 31462422
DOI: 10.1136/bmjspcare-2019-001916 -
Drug and Therapeutics Bulletin Dec 1997
Review
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Enzyme Inhibitors; Esophagitis, Peptic; Humans; Omeprazole; Pantoprazole; Stomach Ulcer; Sulfoxides
PubMed: 9614720
DOI: 10.1136/dtb.1997.351293 -
Klinische Padiatrie Sep 2023Childhood-onset type 1 diabetes mellitus (DM) is a common chronic metabolic disease associated with life-threatening complications. Diabetic ketoacidosis (DKA) is an...
Childhood-onset type 1 diabetes mellitus (DM) is a common chronic metabolic disease associated with life-threatening complications. Diabetic ketoacidosis (DKA) is an acute complication of type 1 DM that has significant mortality mostly due to cerebral edema. Other putative complications of DKA include hypokalemia, hypophosphatemia, hypoglycemia, intracerebral and peripheral venous thrombosis, rhabdomyolysis, acute pancreatitis, and acute kidney injury (AKI) (Murdoch IA et al., Acta Paediatr 1993; 82:498-500).
Topics: Humans; Child; Diabetic Ketoacidosis; Pantoprazole; Acute Disease; Pancreatitis; Diabetes Mellitus, Type 1
PubMed: 36174588
DOI: 10.1055/a-1937-0927 -
The Journal of the Association of... Dec 2022
Topics: Humans; Pantoprazole; Anaphylaxis; Proton Pump Inhibitors; Anti-Ulcer Agents; 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral
PubMed: 37355982
DOI: No ID Found -
Deutsche Medizinische Wochenschrift... Mar 2003A 46-year-old woman presented for an emergency admission because of colic-like upper abdominal pain and markedly impaired general condition. Eight days before admission...
HISTORY
A 46-year-old woman presented for an emergency admission because of colic-like upper abdominal pain and markedly impaired general condition. Eight days before admission she had started and continued to take pantoprazole because of symptoms of gastroesophageal reflux.
INVESTIGATIONS
Clinical examination and laboratory tests indicated abnormal liver functions suggesting hepatitis. Serology largely excluded an infectious, autoimmunological or metabolic cause. Duplex sonography gave no evidence of bile obstruction or Budd-Chiari syndrome.
DIAGNOSIS AND COURSE
The patient's condition and laboratory tests after the drug had been discontinued gradually improved on symptomatic treatment, indicating pantoprazole-induced hepatitis.
CONCLUSION
Intake of proton pump inhibitors is a rare cause but should be considered in the differential diagnosis of hepatitis of uncertain etiology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdomen; Abdominal Pain; Anti-Ulcer Agents; Benzimidazoles; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Liver; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Ultrasonography, Doppler, Duplex
PubMed: 12649798
DOI: 10.1055/s-2003-38050 -
Naunyn-Schmiedeberg's Archives of... Jul 2020The current study was designed to evaluate the potential abatement effect of pantoprazole against cisplatin-induced nephrotoxicity and establishing the possible...
The current study was designed to evaluate the potential abatement effect of pantoprazole against cisplatin-induced nephrotoxicity and establishing the possible protective mechanisms. Thirty-two male mice were allocated for treatment with saline, single dose of cisplatin (10 mg/kg/i.p), pantoprazole (30 mg/kg/once daily) for 5 days or combination of pantoprazole and cisplatin for 5 days. Urine, blood, and both kidneys were collected for further evaluations. Pantoprazole significantly countermand cisplatin-induced disfigurement of renal histology, kidney weight to body weight ratio, serum levels of creatinine and urea, and microalbuminuria. Furthermore, pantoprazole mostly normalized cisplatin-induced distortion of renal levels of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6, interleukin-10) and renal content of apoptosis regulating protein expressions (Bax, Bcl2, and active caspase 3). In addition, pantoprazole significantly subsided cisplatin-induced distortion of renal lipid peroxidation marker (MDA), renal superoxide dismutase, and catalase activities and renal reduced glutathione content. This study provides an evidence for the protective utility of short-term pantoprazole against cisplatin-induced nephrotoxicity in mice. The protective mechanism of pantoprazole could be through diminution of cisplatin-induced inflammation, oxidative stress, and their subsequent apoptotic renal cell death via abatement of apoptosis regulating protein expressions (Bax, Bcl2, and active caspase3).
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cisplatin; Cytokines; Inflammation; Kidney Diseases; Lipid Peroxidation; Male; Mice; Oxidative Stress; Pantoprazole; Proto-Oncogene Proteins c-bcl-2; bcl-2-Associated X Protein
PubMed: 31950223
DOI: 10.1007/s00210-020-01823-3 -
Arab Journal of Gastroenterology : the... Feb 2023The study was designed to detect novel Adverse Events (AEs) of pantoprazole by disproportionality analysis in the FDA (Food and Drug Administration) database of Adverse...
BACKGROUND AND STUDY AIM
The study was designed to detect novel Adverse Events (AEs) of pantoprazole by disproportionality analysis in the FDA (Food and Drug Administration) database of Adverse Event Reporting System (FAERS) using Data Mining Algorithms (DMAs). Pantoprazole, the most commonly over-utilized Over The Counter (OTC) medication, was selected to assess any short-term or long-term AEs. The study aimed to analyze the novel adverse events of pantoprazole using the FAERS database.
MATERIALS AND METHODS
A retrospective case/non-case disproportionality analysis was performed in the FAERS database. This study was based on AEs reported to FAERS from 2006Q1-2021Q3. Openvigil 2.1 was used for data extraction. Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Information Component (IC) were applied to measure the disproportionality in reporting. A value of ROR-1.96SE > 1, PRR ≥ 2, and IC-2SD > 0 were considered as the threshold for a positive signal.
RESULTS
A total of 1050 reports of dyspepsia, 7248 reports of hypocalcemia and 995 reports of hyponatremia were identified. A potential positive signal for dyspepsia (ROR-1.96SE = 2.231, PRR = 2.359, IC-2SD = 1.13), hypocalcemia (4.961, 5.45, 2.23) and hyponatremia (3.948, 4.179, 1.92) were identified for pantoprazole.
CONCLUSION
Data mining in the FAERS database produced three potential signals associated with pantoprazole. As a result, further clinical surveillance is needed to quantify and validate potential hazards associated with pantoprazole-related adverse events.
Topics: Humans; Drug-Related Side Effects and Adverse Reactions; Pantoprazole; Adverse Drug Reaction Reporting Systems; Hyponatremia; Retrospective Studies; Dyspepsia; Hypocalcemia
PubMed: 36725376
DOI: 10.1016/j.ajg.2022.10.012